News

Under the terms of the agreement, the Israeli Ministry of Health will fund all costs associated with development of the antiserum and the establishment of a GMP manufacturing

Mr Phillippe will assume the position of CFO from Alexander Krantz, who has served as CFO since October 23, 2006. Mr Krantz will continue to act as president,

His responsibilities included supervision of a pilot plant facility, a drug delivery device laboratory, and a core cell culture facility. Prior to Geron, he was associate director, process

Ferring Pharmaceuticals, USA has announced the commercial availability of degarelix for injection, a new injectable gonadotropin-releasing hormone receptor antagonist approved by the FDA for the treatment of hormone

Solta Medical, a provider of anti-aging solutions, has opened the Solta Medical Aesthetic Center to advance the company’s new product development, facilitate research on the Thermage and Fraxel

For the fourth quarter ended December 31, 2008, revenue from continuing operations was $21.9 million, against $12.4 million for the same period in 2007, and $19.0 million for

2008 Highlights Record revenues of $7.1 million in the last quarter Cash and cash equivalents totalling $2.4 million Restructured its debentures and received new financing facilities from Desjardins

Under the terms of the share purchase agreement, Antonius Stegmann, co-founder and chief scientific officer (CSO) of Virosome Biologicals, will remain CSO of Virosome Biologicals. The acquisition of

According to SyntheMed, Repel-CV is a bioresorbable film designed to be placed over the surface of the heart at the conclusion of an open-heart surgical procedure to reduce